Semaglutide combined with the progestin levonorgestrel synergistically reduced endometrial cancer cell viability by upregulating both GLP-1 and progesterone receptors through a novel molecular cross-talk mechanism.
PR-low tumors also respondedThe semaglutide + levonorgestrel combination reduced viability even in progesterone receptor-low tumors — which normally resist progestin therapy alone
What the researchers found
Key findings from cell line and patient-derived organoid (PDO) experiments:
1. Endometrial cancer cell lines (Hec50, KLE, Ishikawa) all express GLP-1 receptors (confirmed by qPCR and Western blot)
2. GLP-1R agonist treatment induces its own receptor expression through positive feedback
3. Patient-derived organoids from 6 individuals with grade 1 endometrial carcinomas showed significant viability reduction with levonorgestrel + semaglutide combination — in both progesterone receptor-high AND progesterone receptor-low tumors
4. Most striking: semaglutide upregulated not only membrane GLP-1R but also nuclear progesterone receptors (PR) and membrane progesterone receptors (PGRMC1/2)
5. This creates a synergistic feedback loop: semaglutide makes tumors more responsive to levonorgestrel, while levonorgestrel makes them more responsive to semaglutide
Why it matters
Endometrial cancer is the most common gynecologic cancer, and its incidence is rising alongside obesity rates. For young women who want to preserve fertility, conservative progestin treatment is an alternative to hysterectomy — but response rates are only about 50-75%, and many patients relapse. Adding semaglutide could both address the underlying obesity risk factor and directly enhance progestin therapy through the newly discovered receptor cross-talk. The finding that even progesterone receptor-low tumors (which typically resist progestin therapy) responded to the combination is particularly exciting.
How the study worked
GLP-1R expression was assessed in three endometrial cancer cell lines (Hec50, KLE, Ishikawa) by qPCR and Western blotting. Patient-derived organoids (PDOs) were generated from 6 individuals with grade 1 endometrial carcinomas. PDOs were treated with progesterone, levonorgestrel, semaglutide, or levonorgestrel + semaglutide combination. Viability was measured. Receptor expression changes (GLP-1R, PR, PGRMC1/2) were analyzed to characterize the molecular cross-talk between pathways.
What this study cannot tell us
This is an in vitro study using cell lines and organoids — results may not translate to human tumors in the complex in vivo environment. Only grade 1 endometrial carcinomas were studied (the least aggressive type). Six organoid models is a small number. The mechanism of receptor cross-talk is described but not fully dissected at the signaling pathway level. Whether the combination would be effective in vivo, at what semaglutide doses, and with what safety profile for fertility preservation are all unknown. The positive feedback loop, while potentially beneficial, could also have unintended consequences.
How to read the evidence
This is an in vitro study using cancer cell lines and patient-derived organoids. The combination of established cell lines with patient-derived models adds translational relevance, but no in vivo or clinical data exists. Evidence is at the early preclinical stage with a novel and mechanistically interesting finding.
When this study was published
Published in 2025, this study represents a cutting-edge application of GLP-1 agonists in oncology — an area likely to receive increasing research attention as semaglutide's applications expand.
The bigger picture
This study opens an entirely new therapeutic angle for GLP-1 drugs — direct anticancer activity through receptor cross-talk, not just indirect benefit from weight loss. If GLP-1 receptors on cancer cells can be exploited therapeutically, it could expand semaglutide's applications into oncology. The concept of one drug sensitizing cancer cells to another through receptor upregulation is a well-known strategy in cancer biology (e.g., estrogen receptor modulation in breast cancer), but this is the first demonstration of GLP-1/progesterone receptor cross-talk in endometrial cancer.
Questions still open
- Could adding semaglutide to levonorgestrel IUD therapy improve response rates in women choosing conservative endometrial cancer treatment to preserve fertility?
- Is the GLP-1R/PR receptor cross-talk specific to endometrial cancer, or does it occur in other hormone-sensitive cancers like breast cancer?
- Would the same synergistic effect be seen with other GLP-1 agonists, or is it specific to semaglutide?
Common questions
Why would a diabetes/weight loss drug help treat endometrial cancer?
What is conservative treatment for endometrial cancer?
Read the original research
Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer.
Cancers, 17(4)
Citation
Hagemann, Andrea R; Hagemann, Ian S; Mutch, David G; Devor, Eric J; Malmrose, Paige K; Zhang, Yuping; Morrison, Abigail M; Thiel, Kristina W; Leslie, Kimberly K. (2025). Enhancing Progestin Therapy with a Glucagon-Like Peptide 1 Agonist for the Conservative Management of Endometrial Cancer.. Cancers, 17(4). https://doi.org/10.3390/cancers17040598